Immunotherapeutic Agents in Breast Cancer

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video reviews the latest trials and research on immunotherapeutic agents being tested in breast cancer.

In this video, Leisha A. Emens, MD, PhD, of the Sidney Kimmel Cancer Center, reviews some of the challenges to treating breast cancer patients with an immunotherapeutic approach and highlights the latest trials and research on different immunotherapies being tested in this setting, including PD-1 and PD-L1 blockade in patients with triple-negative breast cancer as well as other subtypes.

Emens gave a presentation on this topic at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Related Content
Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

ASH 2025: Key Anticipated Updates in the Leukemia Landscape

Russ Conroy
December 4th 2025
Article

Updated results at ASH 2025 may support new alternatives to continuous therapy and standard intensive chemotherapy across different leukemia types.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Delving Into the Current State of Clinical Practice in SCLC

Roman Fabbricatore
December 3rd 2025
Article

In a spotlight session at the Chemotherapy Foundation Symposium, Anne Chiang, MD, PhD, covered developments in the field of LS-SCLC.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Tim Cortese
November 15th 2025
Article

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.